AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 292 min read$ZLAB

Edmondson Frazor Titus III sold $72K of ZLAB

Edmondson Frazor Titus III (Chief Legal Officer) sold 4,103 shares of Zai Lab Ltd (ZLAB) at $17.46 on 2026-06-26.

Original reporting
SEC EDGAR · Edmondson Frazor Titus III
Published Jun 29, 2026, 8:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 29, 2026, 8:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ZLAB
Neutral
medium confidence
Mentioned
$ZLAB
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ZLABNeutralLow
01

Why it matters

The newest concrete fact is the specific open-market sale (4,103 shares at $17.4610) and the post-sale holdings (30,346 shares).

02

Market read

Traders may note the insider sale for sentiment, but there is no accompanying operational or financial catalyst in the text.

03

What to watch

Insider sales often occur for non-informational reasons; without context on prior sales, option exercises, or compensation structure, directional inference is weak.

Relevance 3/10Novelty 4/10Timing: Filed 2026-06-29 after-hours; reflects sale executed 2026-06-26.

Background

The filing is an SEC Form 4 insider transaction for Zai Lab Ltd, reported by the Chief Legal Officer.

Company-level read

Ticker impact

$ZLABNeutralMedium confidence
Context

Zai Lab insider Form 4 shows Chief Legal Officer Edmondson Frazor Titus III sold 4,103 shares at $17.4610 on 2026-06-26.

Expected impact

Likely limited near-term impact; may slightly affect sentiment but lacks fundamental catalyst.

Evidence & confidence

Form 4 is primary-source and time-stamped, but the disclosure is an insider sale without accompanying company news (no guidance, trial, deal, or enforcement action).

Market effects

Sector

Minimal—single-company insider transaction without sector-wide signal.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Absence of a disclosed 10b5-1 plan could be interpreted as less “scheduled,” but the transaction is still small and may reflect diversification or tax planning rather than bearish fundamentals.

Key entities

  • issuer
    Zai Lab Ltd

    Subject of the Form 4 insider transaction; Chief Legal Officer reported an open-market sale.

  • insider
    Edmondson Frazor Titus III

    Chief Legal Officer who sold 4,103 shares of Zai Lab on 2026-06-26.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ZLAB insider trading history →

Related articles

OCT 23
$ZLABMedAI 8/10

Zai Lab’s Zoci Shows 82% Response Rate in Early Lung Cancer Study

Zai Lab's (ZLAB) experimental drug Zoci showed an 82% response rate in an early lung cancer study. The 1.6 mg/kg cohort had 81.9% six-month progression-free survival. Zoci with atezolizumab and carboplatin had a 92.3% response rate but increased toxicity. Zai Lab plans a global Phase III study by 2026, aiming to replace chemotherapy in frontline treatment. The company expects multiple program readouts and a potential U.S. biologics license application submission next year.

finance.yahoo.com2 min
OCT 23
$ZLABHighAI 9/10

Why is Zai Lab stock surging today?

Zai Lab (ZLAB) stock rose 7.2% to $23.62 after releasing Phase 1b trial data for its oncology drug zocilurtatug pelitecan, showing an 81.8% response rate. The company also announced a $250M capital raise from institutional investors. Analysts have an average price target above current levels.

investing.com2 min
OCT 23
$ZLABMedAI 8/10

Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer

Zai Lab (ZLAB) reported positive Phase 1b trial results for zocilurtatug pelitecan (zoci) plus atezolizumab in extensive-stage small cell lung cancer (ES-SCLC). The combination achieved an 81.8% response rate and 81.9% 6-month progression-free survival rate. The therapy was well-tolerated, with Grade >3 adverse events in 9.1% of patients. Zai Lab plans to initiate a global Phase 3 trial by year-end 2026.

thailand-business-news.com3 min
OCT 23
$ZLABMedAI 9/10

Zai Lab Limited: Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer

Zai Lab's (ZLAB) drug zocilurtatug pelitecan (zoci) showed 81.8% response rate and 81.9% 6-month progression-free survival in a Phase 1b trial for extensive-stage small cell lung cancer. The combination with atezolizumab was well-tolerated. A Phase 3 trial is planned for 2026. Zai Lab will discuss the data in an investor call.

finanznachrichten.de3 min
OCT 23
$ZLABHighAI 9/10

Zai Lab reports phase 1b trial data for lung cancer treatment

Zai Lab (ZLAB, 9688) reported Phase 1b trial data for zocilurtatug pelitecan with atezolizumab in lung cancer treatment. At 1.6 mg/kg, 81.8% response rate and 81.9% six-month progression-free survival were observed. Adverse events were mostly mild. A triplet regimen showed 92.3% response rate but higher severe adverse events. Zai Lab plans a Phase 3 study by year-end 2026.

investing.com2 min